The fair market values varies based on how many tests are involved in a payable event
For example a screening visit is priced differently than an injection visit which is different than a follow up visit (or call).
They just have to be defended as reasonable and clinical trial organizations have this data which is ultimately negotiated with each site to setup the contact which along with IRB approval and site training are why bringing new sites takes so long.
IMO